Phase 3 Lymphoma Trial, Recruiting NCT05931263 Sponsor: The First Affiliated Hospital with Nanjing Medical University Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT05931263
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a type of blood cancer called peripheral T-cell lymphoma (PTCL), including certain NK/T-cell lymphomas, but not the type that tests positive for a protein called ALK — and whose cancer responded to their first round of treatment (either completely or partially).
  • People whose kidneys are working well enough to meet specific function levels, as measured by blood and urine tests (confirm with trial site for exact values).
  • People whose liver is functioning within acceptable ranges, based on standard blood tests.
  • People whose lungs are working at 50% or more of the expected level for their age and size.
  • People whose heart is pumping well (left ventricle ejection fraction of at least 50%) and who have no symptoms from any irregular heartbeat.
  • People aged between 18 and 65 years old, of any gender.
  • People who are generally well enough to carry out daily activities, rated 0 or 1 on a standard medical fitness scale (ECOG scale).
  • People whose blood cell counts and stem cell levels meet specific minimum thresholds, as measured by blood tests (confirm with trial site for exact values).
  • People whose life expectancy is at least 3 months.
  • People who are willing and able to sign a written consent form agreeing to take part.

Who may not be able to join:

  • People whose lymphoma has spread to the brain or spinal cord.
  • People with an active hepatitis B or hepatitis C infection.
  • People who currently have an active infection of any kind.
  • People living with HIV.
  • People who have cirrhosis or scarring of the liver.
  • People whose heart tracing (ECG) shows a specific type of irregular reading (QTc interval greater than 500ms).
  • People who have a mental disability or are otherwise unable to give informed consent.
  • People with a history of drug or alcohol misuse that could affect the study results.
  • Women who are pregnant, breastfeeding, or of childbearing age who are unwilling to use contraception during the trial.
  • People whom the trial researchers determine are not suitable to participate, for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: wei xu, : China, Jiangsu Hematological Department, People's Hospital of Jiangsu Province

Phone: 86-25-68302182

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 June 2023
Est. completion
1 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-y PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov